Antibody molecules which bind cd79

Patent metadata

Field	Value
Publication number	US-2018201678-A1
Application number	US-201615743764-A
Country	US
Kind code	A1
Filing date	Jul 15, 2016
Priority date	Jul 16, 2015
Publication date	Jul 19, 2018
Grant date	—

Abstract

The present disclosure relates to antibody molecules comprising a binding domain specific to CD79, said binding domain comprising SEQ ID NO: 1, 2, 3 or 4, and/or SEQ ID NO: 5, 6 and 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

First claim

1 . An antibody molecule comprising a binding domain specific to CD79 wherein the binding domain comprises a heavy chain variable domain (VH) comprising:
CDRH1 of formula (I):

(SEQ ID NO: 1)

GFSLX 1 NYX 2 X 3 X 4

wherein X 1 is S or N, X 2 is V or A, X 3 is V or M and X 4 is S or V, CDRH2 of formula (II):

(SEQ ID NO: 2)

IIYX 5 X 6 X 7 X 8 X 9 X 10 X 11 YAX 12 WAKG

wherein X 5 is V or I, X 6 is S or E, X 7 is T or G and X 8 is N or G, X 9 is T or A, X 10 is T or Y, X 11 is W or absent, X 12 is N or S, CDHR3 is

(SEQ ID NO: 3)

EPYEPYDDSNIYYGMDP

or

(SEQ ID NO: 4)

DAGHSDVDVLDI,

and
a light chain variable domain (VL),
wherein the light chain variable domain (VL) comprises:
a CDRL1 of formula (III):

(SEQ ID NO: 5)

QX 13 SQSX 14 X 15 X 16 X 17 NX 18 LA

wherein X 13 is A or S, X 14 is V or I, X 15 is V or Y and X 16 is N or S, X 17 is G or N, and X 18 is Y or D;
a CDRL2 of formula (IV):

(SEQ ID NO: 6)

X 19 ASX 20 LAS

wherein X 19 is S or E, and X 20 T or K;
a CDRL3 has a formula (V):

(SEO ID NO: 7)

X 21 GX 22 X 23 SX 24 X 25 X 26 X 27 X 28 X 29 X 30 A

wherein X 21 is L or Q, X 22 is G or E, X 23 is G or F, X 24 is C, S or G (particularly S or G), X 25 is S or G, X 26 is D, S or E, X 27 is H, G, A, S or C (particularly H, G, A or S), X 28 is I or D, X 29 is C, S or absent and X 30 is N or absent.

2 . (canceled)

3 . The antibody molecule according to claim 1 wherein formula (I) is SEQ ID NO: 8 or 11, such as SEQ ID NO: 8.

4 . The antibody molecule according to claim 1 , wherein formula (II) is SEQ ID NO: 9 or 12, such as SEQ ID NO: 9.

5 . The antibody molecule according to claim 1 , wherein CDRH3 is SEQ ID NO: 3 or 4.

6 . (canceled)

7 . The antibody molecule according to claim 1 , wherein formula (III) is SEQ ID NO: 13 or 19.

8 . The antibody molecule according to claim 1 , wherein formula (IV) is SEQ ID NO: 14 or 20.

9 . The antibody molecule according to claim 1 , wherein formula (V) is independently selected from the group comprising SEQ ID NO: 15, 16, 17, 18, 21, 22, 23 and 24.

10 . The antibody molecule according to claim 1 wherein CDR H1 is SEQ ID NO:8, CDR H2 is SEQ ID NO:9, CDRH3 is SEQ ID NO:4, CDRL1 is SEQ ID NO:13, CDRL2 is SEQ ID NO:14 and CDRL3 is independently selected from SEQ ID NO:15, 16, 17 or 18.

11 . The antibody molecule according to claim 1 wherein CDR H1 is SEQ ID NO:11, CDR H2 is SEQ ID NO:12, CDRH3 is SEQ ID NO:3, CDRL1 is SEQ ID NO:19, CDRL2 is SEQ ID NO:20 and CDRL3 is independently selected from SEQ ID NO:21, 22, 23 or 24.

12 . The antibody molecule according to any one of claim 1 , 3 - 5 , or 7 - 11 wherein VH and VL are humanised.

13 . The antibody molecule according to claim 12 wherein the variable domain of the heavy chain (VH) comprises a human framework region wherein the residue at at least one of positions 24, 37, 48, 49, 67, 71, 73 and 78 is a donor residue and the variable domain of the light chain (VL) comprises a human framework region wherein the residue at at least one of positions 2, 3, 36, 46, 49 and 70 is a donor residue.

14 . The antibody molecule according to claim 12 comprising
a. a VH having the sequence given in SEQ ID NO:34 or 35 and a VL having the sequence given in SEQ ID NO:33 or 250 or
b. a VH having the sequence given in SEQ ID NO:41 or 42 and a VL having the sequence given in SEQ ID NO:40, 341, 342 or 343.

15 . (canceled)

16 . The antibody molecule according to claim 12 , wherein the variable domain of the light chain comprises a sequence having at least 80% identity or similarity to the light chain variable domain of SEQ ID NO:33, 40 or 250 and wherein the variable domain of the heavy chain comprises a sequence having at least 80% identity or similarity to the heavy chain variable domain of SEQ ID NO:34, 35, 41 or 42.

17 . The antibody molecule according to any one of claims 1 to 16 wherein the antibody is:
a. a full length antibody or
b. a scFv, Fv, Fab or Fab′ fragment or
c. a multispecific molecule such as a bispecific or trispecific.

18 - 19 . (canceled)

20 . The antibody molecule according to claim 1 , wherein the molecule format is selected from diabody, scdiabody, triabody, tandem scFv, FabFv, Fab′Fv, FabdsFv, Fab-scFv, Fab-dsscFv, Fab-(dsscFv) 2 diFab, diFab′, tribody, tandem scFv-Fc, scFv-Fc-scFv, scdiabody-Fc, scdiabody-CH3, Ig-scFv, scFv-Ig, V-Ig, Ig-V, Duobody and DVD-Ig.

21 . The antibody molecule according to claim 17 comprising one binding domain which is specific to CD79 and one binding domain which is specific to CD22 or CD45.

22 . The antibody molecule according to claim 21 wherein each binding domain is monospecific.

23 . The antibody molecule according to claim 21 wherein:
a. the bispecific or trispecific molecule comprises no more than one binding domain which is specific to CD22 and no more than one binding domain which is specific to CD79a and/or CD79b; or
b. the bispecific or trispecific molecule comprises no more than one binding domain which is specific to CD45 and no more than one binding domain which is specific to CD79a and/or CD79b, or
c. the binding domain which is specific to CD22 or CD45 and the binding domain which is specific to CD79a and/or CD79b are independently selected from a Fab, scFv, Fv, dsFv and dsscFv.

Assignees

• Ucb Biopharma Sprl

Inventors

• Finney Helene Margaret
• Rapecki Stephen Edward
• Tyson Kerry Louise
• Wright Michael John

Classifications

• C07K2317/622

  Single chain antibody (scFv) · CPC title

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• A61K47/6809

  Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin · CPC title

• A61K47/6867

  the tumour determinant being from a cell of a blood cancer · CPC title

• C07K16/2896

  against molecules with a "CD"-designation, not provided for elsewhere · CPC title